Cormedix gets FDA priority review for Rezzayo label expansion

RegulatoryRezzayoPositive

AI Analysis

Summary

Cormedix announced the FDA granted priority review for a label expansion of Rezzayo. No PDUFA date or indication details were provided in the available text.

Outcome Details

FDA granted priority review for Rezzayo label expansion

Importance:6/10

Sentiment:

0.50

FDApriority reviewlabel expansionsNDA

Related Companies

$CRMD

Read the original article

Published by Seeking Alpha Healthcare on October 19, 2026 1:06 PM

Read Original